Business Wire

Aggreko Awarded for Excellence in Environmental Stewardship

Share

Aggreko plc, the global leader in rental power, heating and cooling, has been recognized by Texas Oil & Gas Awards with its award for Excellence in Environmental Stewardship for the company’s custom Selective Catalytic Reduction (SCR) emissions control technology that helps reduce NOx emissions on temporary large-scale natural gas power plants.

Launched in 2012, the Texas Oil & Gas Awards showcases the great gains being made by upstream, midstream and downstream companies in key areas of corporate social responsibility, the environment, and health and safety. The awards enable companies to celebrate their achievement and demonstrate their commitment to these critical industry issues.

“We are gratified to be recognized with this prestigious award for the work we did for a new cryogenic gas processing facility in the Permian Basin of West Texas,” said Charles Royce, Managing Director, North America. “The job called for us to not only meet state emissions regulations, but also Federal regulations, which meant we had to reduce NOx emissions by 75%. We are helping our customers in their transition to new realities of global energy markets. Globally, the energy sector is going through a major transition; the challenge today is to find the optimal way to secure more energy, affordably and sustainably.”

The Award for Excellence in Environmental Stewardship recognizes efforts, initiatives or technological developments that have minimized or eliminated their environmental footprint within the region. Organizations working in the oil and gas sector that can demonstrate making a positive contribution to the advancement of environmental considerations are eligible. Award winners must demonstrate true innovation in tracking environmental impact, implementation of practices or technology proving environmental benefit, and must demonstrate clear practical application of the solution or initiative in the region and long-term environmental benefits which are also economically sustainable.

Aggreko was awarded for its emissions control technology that surpassed emissions regulations and successfully reduced the NOx emissions up to 90% and Hydro-Carbon, CO and particulate emissions reduction up to 80%, a true first of its kind in the world of Temporary Rental Power Generation. Aggreko’s engineering team designed a 2-phase approach. Phase 1 included 26MW of Natural Gas power generation. Additionally, a custom-built set of SCR (Selective Catalytic Reduction) units were retrofitted atop the exhaust stack of each of the 25 natural gas generators in Phase 1. To ensure the emissions and the overall performance of the system could be monitored in real-time, Aggreko brought in its overseas SCADA (Supervisory Control and Data Acquisition) colleagues for additional support. The ability of the cryogenic plant to utilize its own field gas for fuel also meant that fewer trucks needed to drive the roads to deliver fuel to the site, further reducing costs, and also helping to reduce traffic congestion and preserve the roads. This 26MW temporary power plant with custom-built SCR units and SCADA is a first of its kind and has set the benchmark for clean-burning, large-scale power plants moving forward.

EDITOR’S NOTES

Around the world, people, businesses and countries are striving for a better future - a future that needs power and the right conditions to succeed.

Aggreko works round the clock, making sure everyone gets the electricity, heating and cooling they need, whenever they need it – all powered by our class-leading equipment, trademark passion, unrivalled international experience and local knowledge. From urban development to unique commercial projects and even humanitarian emergencies, we bring our expertise and equipment to any location, from the world’s busiest cities to some of the most remote places on earth.

That’s what has made us the world’s leading provider of modular, mobile power and heating and cooling. We’ve been in business since 1962. We have more than 7,300 employees, operating from around 200 locations in 100 countries. With revenues of approximately GBP 1.7bn (USD 2.2bn or Euros 2bn) in 2017, we are listed on the London Stock Exchange (AGK.L) and have our headquarters in Scotland.

Our business helps transform the lives and livelihoods of individuals, organisations and communities across the globe, in both developed and developing countries and markets.

We operate across all sectors, including oil and gas, petrochemical and refining, utilities, manufacturing, construction, mining and events.

We design and manufacture equipment specifically for these requirements in our factory in Dumbarton, Scotland and work with leading innovators to ensure our equipment offers maximum fuel flexibility, by using gas, diesel (including HFO) and renewable fuel sources.

For more information, please visit our local website at: aggreko.com

Contact information

Deborah Buks
T: +9 (713) 869-0707
E: dbuks@wardcc.com

Lynn Hancock
T: +9 (713) 869-0707
E: lhancock@wardcc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Post Malone and Crocs Launch Fourth Collaboration9.12.2019 20:57:00 EETPress release

Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/ The Post Malone x Crocs Duet Max Clog is an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This is the fourth collaboration between the duo. (Photo: Business Wire) The evolution of the Post Malone x Crocs partnership is evident over th

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EETPress release

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K

Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EETPress release

Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EETPress release

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EETPress release

Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom